A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 12, 2010, Pages 1239-1248

  Al Jarallah, Aishah ^a   Trigatti, Bernardo L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Atheroprotection; Caveolae; Cholesterol; HDL; S1PR; Signaling; Sphingosine 1 phosphate; SR BI

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR BI; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; ATHEROSCLEROSIS; BONE MARROW; CAVEOLA; CELL MIGRATION; CORONARY RISK; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID TRANSPORT; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULARIZATION;

ANIMALS; HUMANS; LIPOPROTEINS, HDL; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION;

EID: 77957941762     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.08.006     Document Type: Review

References (189)

1. Barter P., Kastelein J., Nunn A., Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003, 168:195-211.
2. Cho K.H. Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep. 2009, 42:393-400.
3. Davidson W.S., Thompson T.B. The structure of apolipoprotein A-I in high density lipoproteins. J. Biol. Chem. 2007, 282:22249-22253.
4. Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2009, pp.
5. Heinecke J.W. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J. Lipid Res. 2009, 50(Suppl):S167-S171.
6. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 2008, 54:788-800.
7. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. (Lond.) 2009, 116:87-98.
8. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 2005, 96:1221-1232.
9. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta 1981, 665:408-419.
10. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988, 27:25-29.
11. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta 1993, 1169:291-300.
12. Cheung M.C., Albers J.J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J. Biol. Chem. 1984, 259:12201-12209.
13. Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431-1445.
14. Duchateau P.N., Pullinger C.R., Orellana R.E., Kunitake S.T., Naya-Vigne J., O'Connor P.M., Malloy M.J., Kane J.P. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J. Biol. Chem. 1997, 272:25576-25582.
15. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., Byun J., Vuletic S., Kassim S., Singh P., Chea H., Knopp R.H., Brunzell J., Geary R., Chait A., Zhao X.Q., Elkon K., Marcovina S., Ridker P., Oram J.F., Heinecke J.W. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117:746-756.
16. Scanu A.M., Edelstein C. HDL: bridging past and present with a look at the future. FASEB J. 2008, 22:4044-4054.
17. Reilly M.P., Tall A.R. HDL proteomics: pot of gold or Pandora's box?. J. Clin. Invest. 2007, 117:595-598.
18. Goti D., Hammer A., Galla H.J., Malle E., Sattler W. Uptake of lipoprotein-associated alpha-tocopherol by primary porcine brain capillary endothelial cells. J. Neurochem. 2000, 74:1374-1383.
19. Kayden H.J., Traber M.G. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J. Lipid Res. 1993, 34:343-358.
20. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?. Biochim. Biophys. Acta 2002, 1582:132-137.
21. Clarke J.T. The glycosphingolipids of human plasma lipoproteins. Can. J. Biochem. 1981, 59:412-417.
22. Gong M., Wilson M., Kelly T., Su W., Dressman J., Kincer J., Matveev S.V., Guo L., Guerin T., Li X.A., Zhu W., Uittenbogaard A., Smart E.J. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J. Clin. Invest. 2003, 111:1579-1587.
23. Li X.A., Titlow W.B., Jackson B.A., Giltiay N., Nikolova-Karakashian M., Uittenbogaard A., Smart E.J. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 2002, 277:11058-11063.
24. Barr D.P., Russ E.M., Eder H.A. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am. J. Med. 1951, 11:480-493.
25. Boyd G.S., Oliver M.F. The circulating lipids and lipoproteins in coronary artery disease. Postgrad. Med. J. 1957, 32:2-6. passim.
26. Jacobs D.R., Mebane I.L., Bangdiwala S.I., Criqui M.H., Tyroler H.A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 1990, 131:32-47.
27. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124:S11-S20. Suppl.
28. Gordon D.J., Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J. Med. 1989, 321:1311-1316.
29. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 1983, 52:223-261.
30. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., Steyn K., Sanderson J.E., Hasani M., Volkova E., Kazmi K., Yusuf S. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
31. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.A., Guertin M.C., Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. Jama 2007, 297:1675-1682.
32. Shaw J.A., Bobik A., Murphy A., Kanellakis P., Blombery P., Mukhamedova N., Woollard K., Lyon S., Sviridov D., Dart A.M. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008, 103:1084-1091.
33. Phan B.A., Chu B., Polissar N., Hatsukami T.S., Yuan C., Zhao X.Q. Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. Int. J. Cardiovasc. Imaging 2007, 23:337-342.
34. Choudhury R.P., Rong J.X., Trogan E., Elmalem V.I., Dansky H.M., Breslow J.L., Witztum J.L., Fallon J.T., Fisher E.A. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1904-1909.
35. von Birgelen C., Hartmann M., Mintz G.S., Baumgart D., Schmermund A., Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12months) follow-up intravascular ultrasound. Circulation 2003, 108:2757-2762.
36. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. Jama 2007, 297:499-508.
37. Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 1968, 9:155-167.
38. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem. 1999, 68:523-558.
39. Williams D.L., Connelly M.A., Temel R.E., Swarnakar S., Phillips M.C., de la Llera-Moya M., Rothblat G.H. Scavenger receptor BI and cholesterol trafficking. Curr. Opin. Lipidol. 1999, 10:329-339.
40. Escola-Gil J.C., Rotllan N., Julve J., Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009, 206:321-327.
41. Ohashi R., Mu H., Wang X., Yao Q., Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 2005, 98:845-856.
42. Schmitz G., Grandl M. The molecular mechanisms of HDL and associated vesicular trafficking mechanisms to mediate cellular lipid homeostasis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1718-1722.
43. Remaley A.T., Stonik J.A., Demosky S.J., Neufeld E.B., Bocharov A.V., Vishnyakova T.G., Eggerman T.L., Patterson A.P., Duverger N.J., Santamarina-Fojo S., Brewer H.B. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem. Biophys. Res. Commun. 2001, 280:818-823.
44. Vaughan A.M., Oram J.F. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J. Lipid Res. 2006, 47:2433-2443.
45. Gelissen I.C., Harris M., Rye K.A., Quinn C., Brown A.J., Kockx M., Cartland S., Packianathan M., Kritharides L., Jessup W. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 2006, 26:534-540.
46. Liadaki K.N., Liu T., Xu S., Ishida B.Y., Duchateaux P.N., Krieger J.P., Kane J., Krieger M., Zannis V.I. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J. Biol. Chem. 2000, 275:21262-21271.
47. de Beer M.C., Durbin D.M., Cai L., Jonas A., de Beer F.C., van der Westhuyzen D.R. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J. Lipid Res. 2001, 42:309-313.
48. Out R., Hoekstra M., de Jager S.C., de Vos P., van der Westhuyzen D.R., Webb N.R., Van Eck M., Biessen E.A., Van Berkel T.J. Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J. Lipid Res. 2005, 46:1172-1181.
49. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J. Biol. Chem. 1998, 273:32920-32926.
50. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387:414-417.
51. Brundert M., Ewert A., Heeren J., Behrendt B., Ramakrishnan R., Greten H., Merkel M., Rinninger F. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:143-148.
52. E.C. Quintao and P.M. Cazita, Lipid transfer proteins: past, present and perspectives, Atherosclerosis. 209 pp. 1-9.
53. Spady D.K. Hepatic clearance of plasma low density lipoproteins. Semin. Liver Dis. 1992, 12:373-385.
54. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 2008, 23:370-378.
55. Cockerill G.W., Saklatvala J., Ridley S.H., Yarwood H., Miller N.E., Oral B., Nithyanathan S., Taylor G., Haskard D.O. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler. Thromb. Vasc. Biol. 1999, 19:910-917.
56. Drew B.G., Fidge N.H., Gallon-Beaumier G., Kemp B.E., Kingwell B.A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl Acad. Sci. USA 2004, 101:6999-7004.
57. Grewal T., de Diego I., Kirchhoff M.F., Tebar F., Heeren J., Rinninger F., et al. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J. Biol. Chem. 2003, 278:16478-16481.
58. Murphy A.J., Chin-Dusting J.P., Sviridov D., Woollard K.J. The anti inflammatory effects of high density lipoproteins. Curr. Med. Chem. 2009, 16:667-675.
59. Robbesyn F., Auge N., Vindis C., Cantero A.V., Barbaras R., Negre-Salvayre A., Salvayre R. High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1206-1212.
60. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1283-1288.
61. Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., Sekiguchi A., Ishiwara M., Im D.S., Sato K., Murakami M., Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 2006, 281:37457-37467.
62. Mineo C., Shaul P.W. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc. Med. 2007, 17:156-161.
63. Mineo C., Yuhanna I.S., Quon M.J., Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003, 278:9142-9149.
64. Valiyaveettil M., Kar N., Ashraf M.Z., Byzova T.V., Febbraio M., Podrez E.A. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008, 111:1962-1971.
65. Zannis V.I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 2006, 84:276-294.
66. Krieger M., Kozarsky K. Influence of the HDL receptor SR-BI on atherosclerosis. Curr. Opin. Lipidol. 1999, 10:491-497.
67. Rigotti A., Miettinen H.E., Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr. Rev. 2003, 24:357-387.
68. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 1994, 269:21003-21009.
69. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
70. Rhainds D., Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int. J. Biochem. Cell Biol. 2004, 36:39-77.
71. Ikemoto M., Arai H., Feng D., Tanaka K., Aoki J., Dohmae N., Takio K., Adachi H., Tsujimoto M., Inoue K. Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I. Proc. Natl Acad. Sci. USA 2000, 97:6538-6543.
72. Yesilaltay A., Kocher O., Pal R., Leiva A., Quinones V., Rigotti A., Krieger M. PDZK1 is required for maintaining hepatic scavenger receptor, class B, type I (SR-BI) steady state levels but not its surface localization or function. J. Biol. Chem. 2006, 281:28975-28980.
73. Ohgami N., Nagai R., Miyazaki A., Ikemoto M., Arai H., Horiuchi S., Nakayama H. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem. 2001, 276:13348-13355.
74. Lund-Katz S., Liu L., Thuahnai S.T., Phillips M.C. High density lipoprotein structure. Front. Biosci. 2003, 8:d1044-d1054.
75. Pilon A., Briand O., Lestavel S., Copin C., Majd Z., Fruchart J.C., Castro G., Clavey V. Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1074-1081.
76. de Beer M.C., Durbin D.M., Cai L., Mirocha N., Jonas A., Webb N.R., de Beer F.C., van Der Westhuyzen D.R. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J. Biol. Chem. 2001, 276:15832-15839.
77. Connelly M.A., Williams D.L. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr. Opin. Lipidol. 2004, 15:287-295.
78. de La Llera-Moya M., Connelly M.A., Drazul D., Klein S.M., Favari E., Yancey P.G., Williams D.L., Rothblat G.H. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J. Lipid Res. 2001, 42:1969-1978.
79. Yancey P.G., de la Llera-Moya M., Swarnakar S., Monzo P., Klein S.M., Connelly M.A., Johnson W.J., Williams D.L., Rothblat G.H. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 2000, 275:36596-36604.
80. Pownall H.J. Detergent-mediated phospholipidation of plasma lipoproteins increases HDL cholesterophilicity and cholesterol efflux via SR-BI. Biochemistry 2006, 45:11514-11522.
81. Thuahnai S.T., Lund-Katz S., Dhanasekaran P., de la Llera-Moya M., Connelly M.A., Williams D.L., Rothblat G.H., Phillips M.C. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J. Biol. Chem. 2004, 279:12448-12455.
82. Ji Y., Jian B., Wang N., Sun Y., Moya M.L., Phillips M.C., Rothblat G.H., Swaney J.B., Tall A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 1997, 272:20982-20985.
83. Jian B., de la Llera-Moya M., Ji Y., Wang N., Phillips M.C., Swaney J.B., Tall A.R., Rothblat G.H. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J. Biol. Chem. 1998, 273:5599-5606.
84. von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 2001, 21:13-27.
85. Brundert M., Heeren J., Bahar-Bayansar M., Ewert A., Moore K.J., Rinninger F. Selective uptake of HDL cholesteryl esters and cholesterol efflux from mouse peritoneal macrophages independent of SR-BI. J. Lipid Res. 2006, 47:2408-2421.
86. Gu X., Kozarsky K., Krieger M. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J. Biol. Chem. 2000, 275:29993-30001.
87. Wang X., Collins H.L., Ranalletta M., Fuki I.V., Billheimer J.T., Rothblat G.H., Tall A.R., Rader D.J. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 2007, 117:2216-2224.
88. Zhang Y., Da Silva J.R., Reilly M., Billheimer J.T., Rothblat G.H., Rader D.J. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 2005, 115:2870-2874.
89. Zhang W., Yancey P.G., Su Y.R., Babaev V.R., Zhang Y., Fazio S., Linton M.F. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2003, 108:2258-2263.
90. Wang X., Rader D.J. Molecular regulation of macrophage reverse cholesterol transport. Curr. Opin. Cardiol. 2007, 22:368-372.
91. Pennings M., Meurs I., Ye D., Out R., Hoekstra M., Van Berkel T.J., Van Eck M. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett. 2006, 580:5588-5596.
92. Out R., Hoekstra M., Spijkers J.A., Kruijt J.K., van Eck M., Bos I.S., Twisk J., Van Berkel T.J. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J. Lipid Res. 2004, 45:2088-2095.
93. Nieland T.J., Penman M., Dori L., Krieger M., Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc. Natl Acad. Sci. USA 2002, 99:15422-15427.
94. Ji Y., Wang N., Ramakrishnan R., Sehayek E., Huszar D., Breslow J.L., Tall A.R. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J. Biol. Chem. 1999, 274:33398-33402.
95. Varban M.L., Rinninger F., Wang N., Fairchild-Huntress V., Dunmore J.H., Fang Q., Gosselin M.L., Dixon K.L., Deeds J.D., Acton S.L., Tall A.R., Huszar D. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc. Natl Acad. Sci. USA 1998, 95:4619-4624.
96. Mardones P., Quinones V., Amigo L., Moreno M., Miquel J.F., Schwarz M., Miettinen H.E., Trigatti B., Krieger M., VanPatten S., Cohen D.E., Rigotti A. Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J. Lipid Res. 2001, 42:170-180.
97. Sehayek E., Ono J.G., Shefer S., Nguyen L.B., Wang N., Batta A.K., Salen G., Smith J.D., Tall A.R., Breslow J.L. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc. Natl Acad. Sci. USA 1998, 95:10194-10199.
98. Ueda Y., Royer L., Gong E., Zhang J., Cooper P.N., Francone O., Rubin E.M. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J. Biol. Chem. 1999, 274:7165-7171.
99. Trigatti B., Rayburn H., Vinals M., Braun A., Miettinen H., Penman M., Hertz M., Schrenzel M., Amigo L., Rigotti A., Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl Acad. Sci. USA 1999, 96:9322-9327.
100. Van Eck M., Bos I.S., Hildebrand R.B., Van Rij B.T., Van Berkel T.J. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am. J. Pathol. 2004, 165:785-794.
101. Ueda Y., Gong E., Royer L., Cooper P.N., Francone O.L., Rubin E.M. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J. Biol. Chem. 2000, 275:20368-20373.
102. Kozarsky K.F., Donahee M.H., Glick J.M., Krieger M., Rader D.J. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2000, 20:721-727.
103. Covey S.D., Krieger M., Wang W., Penman M., Trigatti B.L. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1589-1594.
104. Arai T., Wang N., Bezouevski M., Welch C., Tall A.R. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 1999, 274:2366-2371.
105. Braun A., Trigatti B.L., Post M.J., Sato K., Simons M., Edelberg J.M., Rosenberg R.D., Schrenzel M., Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 2002, 90:270-276.
106. Arai T., Rinninger F., Varban L., Fairchild-Huntress V., Liang C.P., Chen W., Seo T., Deckelbaum R., Huszar D., Tall A.R. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. Proc. Natl Acad. Sci. USA 1999, 96:12050-12055.
107. Huby T., Doucet C., Dachet C., Ouzilleau B., Ueda Y., Afzal V., Rubin E., Chapman M.J., Lesnik P. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J. Clin. Invest. 2006, 116:2767-2776.
108. Kocher O., Yesilaltay A., Shen C.H., Zhang S., Daniels K., Pal R., Chen J., Krieger M. Influence of PDZK1 on lipoprotein metabolism and atherosclerosis. Biochim. Biophys. Acta 2008, 1782:310-316.
109. Kocher O., Yesilaltay A., Cirovic C., Pal R., Rigotti A., Krieger M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem. 2003, 278:52820-52825.
110. Braun A., Zhang S., Miettinen H.E., Ebrahim S., Holm T.M., Vasile E., Post M.J., Yoerger D.M., Picard M.H., Krieger J.L., Andrews N.C., Simons M., Krieger M. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc. Natl Acad. Sci. USA 2003, 100:7283-7288.
111. Braun A., Yesilaltay A., Acton S., Broschat K.O., Krul E.S., Napawan N., Stagliano N., Krieger M. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 2008, 198:77-84.
112. Karackattu S.L., Trigatti B., Krieger M. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:548-554.
113. Karackattu S.L., Picard M.H., Krieger M. Lymphocytes are not required for the rapid onset of coronary heart disease in scavenger receptor class B type I/apolipoprotein E double knockout mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:803-808.
114. Zhang S., Picard M.H., Vasile E., Zhu Y., Raffai R.L., Weisgraber K.H., Krieger M. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 2005, 111:3457-3464.
115. Yesilaltay A., Daniels K., Pal R., Krieger M., Kocher O. Loss of PDZK1 causes coronary artery occlusion and myocardial infarction in Paigen diet-fed apolipoprotein E deficient mice. PLoS ONE 2009, 4:e8103.
116. Mineo C., Shaul P.W. Circulating cardiovascular disease risk factors and signaling in endothelial cell caveolae. Cardiovasc. Res. 2006, 70:31-41.
117. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98:1352-1364.
118. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., Corti R., Ruschitzka F., Luscher T.F., Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002, 105:1399-1402.
119. Bisoendial R.J., Hovingh G.K., Levels J.H., Lerch P.G., Andresen I., Hayden M.R., Kastelein J.J., Stroes E.S. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003, 107:2944-2948.
120. Levkau B., Hermann S., Theilmeier G., van der Giet M., Chun J., Schober O., Schafers M. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 2004, 110:3355-3359.
121. Cohen R.A. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. 1995, 38:105-128.
122. Shaul P.W. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 2002, 64:749-774.
123. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J. Med. 1993, 329:2002-2012.
124. Kuhlencordt P.J., Gyurko R., Han F., Scherrer-Crosbie M., Aretz T.H., Hajjar R., Picard M.H., Huang P.L. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001, 104:448-454.
125. Kauser K., da Cunha V., Fitch R., Mallari C., Rubanyi G.M. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1679-H1685.
126. Yang R., Powell-Braxton L., Ogaoawara A.K., Dybdal N., Bunting S., Ohneda O., Jin H. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2762-2768.
127. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G., Mendelsohn M.E., Hobbs H.H., Shaul P.W. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
128. Assanasen C., Mineo C., Seetharam D., Yuhanna I.S., Marcel Y.L., Connelly M.A., Williams D.L., de la Llera-Moya M., Shaul P.W., Silver D.L. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J. Clin. Invest. 2005, 115:969-977.
129. Uittenbogaard A., Shaul P.W., Yuhanna I.S., Blair A., Smart E.J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 2000, 275:11278-11283.
130. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., Seedorf U., Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 2001, 276:34480-34485.
131. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. 2000, 272:872-876.
132. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2158-2166.
133. Dimmeler S., Haendeler J., Zeiher A.M. Regulation of endothelial cell apoptosis in atherothrombosis. Curr. Opin. Lipidol. 2002, 13:531-536.
134. Li D., Yang B., Mehta J.L. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am. J. Physiol. 1998, 275:H568-H576.
135. Choy J.C., Granville D.J., Hunt D.W., McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J. Mol. Cell. Cardiol. 2001, 33:1673-1690.
136. Dimmeler S., Breitschopf K., Haendeler J., Zeiher A.M. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J. Exp. Med. 1999, 189:1815-1822.
137. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J. Med. 1998, 338:1042-1050.
138. Strawn W.B., Ferrario C.M. Mechanisms linking angiotensin II and atherogenesis. Curr. Opin. Lipidol. 2002, 13:505-512.
139. Cao W., Murao K., Imachi H., Yu X., Abe H., Yamauchi A., et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004, 64:1515-1521.
140. Kwon Y.G., Min J.K., Kim K.M., Lee D.J., Billiar T.R., Kim Y.M. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J. Biol. Chem. 2001, 276:10627-10633.
141. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., Ui M., Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 2001, 276:31780-31785.
142. Li X., Guo L., Dressman J.L., Asmis R., Smart E.J. A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. J. Biol. Chem. 2005, 280:19087-19096.
143. Seetharam D., Mineo C., Gormley A.K., Gibson L.L., Vongpatanasin W., Chambliss K.L., Hahner L.D., Cummings M.L., Kitchens R.L., Marcel Y.L., Rader D.J., Shaul P.W. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 2006, 98:63-72.
144. Kawasaki K., Smith R.S., Hsieh C.M., Sun J., Chao J., Liao J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 2003, 23:5726-5737.
145. Rossig L., Dimmeler S., Zeiher A.M. Apoptosis in the vascular wall and atherosclerosis. Basic Res. Cardiol. 2001, 96:11-22.
146. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Godecke A., Ishii I., Kleuser B., Schafers M., Fobker M., Zidek W., Assmann G., Chun J., Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
147. Zhu W., Saddar S., Seetharam D., Chambliss K.L., Longoria C., Silver D.L., Yuhanna I.S., Shaul P.W., Mineo C. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ. Res. 2008, 102:480-487.
148. Tanimoto T., Lungu A.O., Berk B.C. Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ. Res. 2004, 94:1050-1058.
149. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., Wattenberg B.W. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003, 22:5491-5500.
150. Landeen L.K., Aroonsakool N., Haga J.H., Hu B.S., Giles W.R. Sphingosine-1-phosphate receptor expression in cardiac fibroblasts is modulated by in vitro culture conditions. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2698-H2711.
151. Mardones P., Strobel P., Miranda S., Leighton F., Quinones V., Amigo L., Rozowski J., Krieger M., Rigotti A. Alpha-tocopherol metabolism is abnormal in scavenger receptor class B type I (SR-BI)-deficient mice. J. Nutr. 2002, 132:443-449.
152. B. Engelmann and M.K. Wiedmann, Cellular phospholipid uptake: Flexible paths to coregulate the functions of intracellular lipids, Biochim Biophys Acta.
153. Rodriguez C., Gonzalez-Diez M., Badimon L., Martinez-Gonzalez J. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 2009, 101:665-673.
154. Sattler K., Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc. Res. 2009, 82:201-211.
155. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., Ui M., Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 2000, 352(Pt 3):809-815.
156. Igarashi J., Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J. Biol. Chem. 2001, 276:36281-36288.
157. Igarashi J., Miyoshi M., Hashimoto T., Kubota Y., Kosaka H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 2007, 150:470-479.
158. Hisamoto K., Ohmichi M., Kurachi H., Hayakawa J., Kanda Y., Nishio Y., Adachi K., Tasaka K., Miyoshi E., Fujiwara N., Taniguchi N., Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 2001, 276:3459-3467.
159. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P., German Z., Sherman T.S., Mendelsohn M.E., Anderson R.G., Shaul P.W. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 2000, 87:E44-E52.
160. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., Shaul P.W. ERbeta has nongenomic action in caveolae. Mol. Endocrinol. 2002, 16:938-946.
161. Kuvin J.T., Ramet M.E., Patel A.R., Pandian N.G., Mendelsohn M.E., Karas R.H. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. 2002, 144:165-172.
162. de la Llera-Moya M., Rothblat G.H., Connelly M.A., Kellner-Weibel G., Sakr S.W., Phillips M.C., Williams D.L. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J. Lipid Res. 1999, 40:575-580.
163. Kellner-Weibel G., de La Llera-Moya M., Connelly M.A., Stoudt G., Christian A.E., Haynes M.P., Williams D.L., Rothblat G.H. Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry 2000, 39:221-229.
164. Williams D.L., Wong J.S., Hamilton R.L. SR-BI is required for microvillar channel formation and the localization of HDL particles to the surface of adrenocortical cells in vivo. J. Lipid Res. 2002, 43:544-549.
165. Reaven E., Leers-Sucheta S., Nomoto A., Azhar S. Expression of scavenger receptor class B type 1 (SR-BI) promotes microvillar channel formation and selective cholesteryl ester transport in a heterologous reconstituted system. Proc. Natl Acad. Sci. USA 2001, 98:1613-1618.
166. Parathath S., Connelly M.A., Rieger R.A., Klein S.M., Abumrad N.A., De La Llera-Moya M., Iden C.R., Rothblat G.H., Williams D.L. Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36. J. Biol. Chem. 2004, 279:41310-41318.
167. Gu X., Trigatti B., Xu S., Acton S., Babitt J., Krieger M. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J. Biol. Chem. 1998, 273:26338-26348.
168. Chang T.Y., Chang C.C., Ohgami N., Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol. 2006, 22:129-157.
169. Wang P.Y., Liu P., Weng J., Sontag E., Anderson R.G. A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity. EMBO J. 2003, 22:2658-2667.
170. Zhang Y., Ahmed A.M., McFarlane N., Capone C., Boreham D.R., Truant R., Igdoura S.A., Trigatti B.L. Regulation of SR-BI-mediated selective lipid uptake in Chinese hamster ovary-derived cells by protein kinase signaling pathways. J. Lipid Res. 2007, 48:405-416.
171. Osada Y., Sunatani T., Kim I.S., Nakanishi Y., Shiratsuchi A. Signalling pathway involving GULP, MAPK and Rac1 for SR-BI-induced phagocytosis of apoptotic cells. J. Biochem. 2009, 145:387-394.
172. Baranova I.N., Vishnyakova T.G., Bocharov A.V., Kurlander R., Chen Z., Kimelman M.L., Remaley A.T., Csako G., Thomas F., Eggerman T.L., Patterson A.P. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 2005, 280:8031-8040.
173. Okajima F., Sato K., Kimura T. Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr. J. 2009, 56:317-334.
174. Corson M.A., James N.L., Latta S.E., Nerem R.M., Berk B.C., Harrison D.G. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ. Res. 1996, 79:984-991.
175. Michel T., Li G.K., Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 1993, 90:6252-6256.
176. Garcia-Cardena G., Fan R., Stern D.F., Liu J., Sessa W.C. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 1996, 271:27237-27240.
177. Boo Y.C., Sorescu G., Boyd N., Shiojima I., Walsh K., Du J., Jo H. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J. Biol. Chem. 2002, 277:3388-3396.
178. Butt E., Bernhardt M., Smolenski A., Kotsonis P., Frohlich L.G., Sickmann A., Meyer H.E., Lohmann S.M., Schmidt H.H. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem. 2000, 275:5179-5187.
179. Davis M.E., Cai H., Drummond G.R., Harrison D.G. Shear stress regulates endothelial nitric oxide synthase expression through c-Src by divergent signaling pathways. Circ. Res. 2001, 89:1073-1080.
180. Harris M.B., Ju H., Venema V.J., Liang H., Zou R., Michell B.J., Chen Z.P., Kemp B.E., Venema R.C. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem. 2001, 276:16587-16591.
181. Gallis B., Corthals G.L., Goodlett D.R., Ueba H., Kim F., Presnell S.R., Figeys D., Harrison D.G., Berk B.C., Aebersold R., Corson M.A. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem. 1999, 274:30101-30108.
182. Montagnani M., Chen H., Barr V.A., Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem. 2001, 276:30392-30398.
183. Thomas S.R., Chen K., Keaney J.F. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J. Biol. Chem. 2002, 277:6017-6024.
184. Michell B.J., Chen Z., Tiganis T., Stapleton D., Katsis F., Power D.A., Sim A.T., Kemp B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem. 2001, 276:17625-17628.
185. Fleming I., Bauersachs J., Schafer A., Scholz D., Aldershvile J., Busse R. Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 1999, 96:1123-1128.
186. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 1999, 103:401-406.
187. Bernier S.G., Haldar S., Michel T. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J. Biol. Chem. 2000, 275:30707-30715.
188. Shaul P.W., Smart E.J., Robinson L.J., German Z., Yuhanna I.S., Ying Y., Anderson R.G., Michel T. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 1996, 271:6518-6522.
189. Honda H.M., Wakamatsu B.K., Goldhaber J.I., Berliner J.A., Navab M., Weiss J.N. High-density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells. Atherosclerosis 1999, 143:299-306.